Maureen O Meade1,2, Duncan Young3, Steven Hanna1,2, Qi Zhou1,2, Thomas E Bachman4, Casper Bollen5, Arthur S Slutsky6,7,8, Sarah E Lamb3, Neill K J Adhikari6,7,9, Spyros D Mentzelopoulos10, Deborah J Cook1,2, Sachin Sud11, Roy G Brower12, B Taylor Thompson13, Sanjoy Shah14, Alex Stenzler15, Gordon Guyatt1,2, Niall D Ferguson6,7,16,17. 1. 1 Department of Medicine and. 2. 2 Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada. 3. 3 University of Oxford, Oxford, United Kingdom. 4. 4 Czech Technical University-Prague, Kladno, Czech Republic. 5. 5 Wilhelmina Children's Hospital, Utrecht, the Netherlands. 6. 6 Interdepartmental Division of Critical Care Medicine. 7. 8 Department of Medicine, and. 8. 7 Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada. 9. 9 Department of Critical Care Medicine, Sunnybrook Health Science Centre, Toronto, Canada. 10. 10 Athens Medical School, Evaggelismos General Hospital, Athens, Greece. 11. 11 Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada. 12. 12 Johns Hopkins University School of Medicine, Baltimore, Maryland. 13. 13 Harvard University, Boston, Massachusetts. 14. 14 University Hospitals Bristol, National Health Service Foundation Trust, Bristol, United Kingdom. 15. 15 12th Man Technologies, Garden Grove, California; and. 16. 16 Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada. 17. 17 Division of Respirology, Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto General Research Institute, Toronto, Canada.
Abstract
RATIONALE: High-frequency oscillatory ventilation (HFOV) is theoretically beneficial for lung protection, but the results of clinical trials are inconsistent, with study-level meta-analyses suggesting no significant effect on mortality. OBJECTIVES: The aim of this individual patient data meta-analysis was to identify acute respiratory distress syndrome (ARDS) patient subgroups with differential outcomes from HFOV. METHODS: After a comprehensive search for trials, two reviewers independently identified randomized trials comparing HFOV with conventional ventilation for adults with ARDS. Prespecified effect modifiers were tested using multivariable hierarchical logistic regression models, adjusting for important prognostic factors and clustering effects. MEASUREMENTS AND MAIN RESULTS: Data from 1,552 patients in four trials were analyzed, applying uniform definitions for study variables and outcomes. Patients had a mean baseline PaO2/FiO2 of 114 ± 39 mm Hg; 40% had severe ARDS (PaO2/FiO2 <100 mm Hg). Mortality at 30 days was 321 of 785 (40.9%) for HFOV patients versus 288 of 767 (37.6%) for control subjects (adjusted odds ratio, 1.17; 95% confidence interval, 0.94-1.46; P = 0.16). This treatment effect varied, however, depending on baseline severity of hypoxemia (P = 0.0003), with harm increasing with PaO2/FiO2 among patients with mild-moderate ARDS, and the possibility of decreased mortality in patients with very severe ARDS. Compliance and body mass index did not modify the treatment effect. HFOV increased barotrauma risk compared with conventional ventilation (adjusted odds ratio, 1.75; 95% confidence interval, 1.04-2.96; P = 0.04). CONCLUSIONS: HFOV increases mortality for most patients with ARDS but may improve survival among patients with severe hypoxemia on conventional mechanical ventilation.
RATIONALE: High-frequency oscillatory ventilation (HFOV) is theoretically beneficial for lung protection, but the results of clinical trials are inconsistent, with study-level meta-analyses suggesting no significant effect on mortality. OBJECTIVES: The aim of this individual patient data meta-analysis was to identify acute respiratory distress syndrome (ARDS) patient subgroups with differential outcomes from HFOV. METHODS: After a comprehensive search for trials, two reviewers independently identified randomized trials comparing HFOV with conventional ventilation for adults with ARDS. Prespecified effect modifiers were tested using multivariable hierarchical logistic regression models, adjusting for important prognostic factors and clustering effects. MEASUREMENTS AND MAIN RESULTS: Data from 1,552 patients in four trials were analyzed, applying uniform definitions for study variables and outcomes. Patients had a mean baseline PaO2/FiO2 of 114 ± 39 mm Hg; 40% had severe ARDS (PaO2/FiO2 <100 mm Hg). Mortality at 30 days was 321 of 785 (40.9%) for HFOVpatients versus 288 of 767 (37.6%) for control subjects (adjusted odds ratio, 1.17; 95% confidence interval, 0.94-1.46; P = 0.16). This treatment effect varied, however, depending on baseline severity of hypoxemia (P = 0.0003), with harm increasing with PaO2/FiO2 among patients with mild-moderate ARDS, and the possibility of decreased mortality in patients with very severe ARDS. Compliance and body mass index did not modify the treatment effect. HFOV increased barotrauma risk compared with conventional ventilation (adjusted odds ratio, 1.75; 95% confidence interval, 1.04-2.96; P = 0.04). CONCLUSIONS:HFOV increases mortality for most patients with ARDS but may improve survival among patients with severe hypoxemia on conventional mechanical ventilation.
Authors: Davide Chiumello; Laurent Brochard; John J Marini; Arthur S Slutsky; Jordi Mancebo; V Marco Ranieri; B Taylor Thompson; Laurent Papazian; Marcus J Schultz; Marcelo Amato; Luciano Gattinoni; Alain Mercat; Antonio Pesenti; Daniel Talmor; Jean-Louis Vincent Journal: Crit Care Date: 2017-09-12 Impact factor: 9.097
Authors: Federico Angriman; Bruno L Ferreyro; Lachlan Donaldson; Brian H Cuthbertson; Niall D Ferguson; Casper W Bollen; Thomas E Bachman; François Lamontagne; Neill K J Adhikari Journal: Intensive Care Med Date: 2019-10-29 Impact factor: 17.440